Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Cimetidine, widely recognized by its brand name Tagamet, is a pioneering pharmaceutical agent belonging to the class of histamine H2-receptor antagonists. With the chemical formula C10H16N6S and the CAS registry number 51481-61-9, this compound represents a landmark achievement in gastrointestinal medicine. First introduced in the early 1970s, it was the first drug of its kind to effectively reduce stomach acid production, revolutionizing the treatment of peptic ulcer disease.
The primary mechanism of action involves the competitive inhibition of histamine at the H2 receptors located on the parietal cells of the gastric mucosa. By blocking these receptors, cimetidine significantly suppresses both basal and stimulated gastric acid secretion. This reduction in acidity creates a favorable environment for the healing of erosions and ulcers within the esophagus, stomach, and duodenum. Consequently, it is extensively prescribed for managing conditions such as gastroesophageal reflux disease (GERD), active duodenal and gastric ulcers, and pathological hypersecretory states like Zollinger-Ellison syndrome. Furthermore, it is occasionally utilized off-label for the prevention of stress-related mucosal damage in critically ill patients.
Beyond its therapeutic applications, cimetidine possesses unique pharmacological properties that distinguish it from other H2 blockers. Notably, it acts as an inhibitor of several cytochrome P450 enzymes in the liver, which can alter the metabolism of concurrent medications, leading to potential drug-drug interactions. While newer agents like ranitidine and famotidine have largely replaced it due to improved safety profiles and fewer interactions, cimetidine remains a cost-effective and valuable option in various clinical settings globally. Its historical significance lies not only in its efficacy but also in demonstrating how rational drug design based on receptor theory can lead to transformative medical therapies. Today, generic formulations are widely available, ensuring continued accessibility for patients requiring long-term acid suppression therapy.